Ginkgo Bioworks
DNA
184 hedge funds and large institutions have $359M invested in Ginkgo Bioworks in 2026 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 69 increasing their positions, 39 reducing their positions, and 19 closing their positions.
243% more call options, than puts
Call options by funds: $8.4M | Put options by funds: $2.45M
82% more capital invested
Capital invested by funds: $197M → $359M (+$162M)
77% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 39
63% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 19
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
5% more funds holding
Funds holding: 175 → 184 (+9)
3.07% more ownership
Funds ownership: 64.74% → 67.82% (+3.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.36M |
| 2 |
EAM
Erste Asset Management
Vienna,
Austria
|
+$4.93M |
| 3 |
Renaissance Technologies
New York
|
+$3.67M |
| 4 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
+$3.11M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$2.7M |
| 2 |
Morgan Stanley
New York
|
-$2.64M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$2.18M |
| 4 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$1.08M |
| 5 |
PEAK6
Chicago,
Illinois
|
-$896K |
DNA Hedge Fund Activity: Q2 2026 in Review
184 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks (DNA) for Q2 2026, worth a combined $359M — up 82% from $197M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new DNA positions and 19 closed out — a net gain of 12 holders — while 69 added to existing stakes and 39 trimmed.
The largest buyer was BlackRock, adding an estimated $5.36M. The largest seller was Goldman Sachs, cutting an estimated $2.7M.
- 184 institutional investors held Ginkgo Bioworks (DNA) as of Q2 2026, up from 175 in Q1 2026.
- Funds reported $359M of Ginkgo Bioworks stock for Q2 2026, up 82% quarter-over-quarter.
- 31 funds opened new Ginkgo Bioworks positions in Q2 2026 and 19 closed out, a net change of +12 holders.
- The largest Ginkgo Bioworks buyer in Q2 2026 was BlackRock, an estimated $5.36M added.
- The largest Ginkgo Bioworks seller in Q2 2026 was Goldman Sachs, an estimated $2.7M sold.
Based on aggregated 13F filings for Q2 2026.